Copertura documentale

Il Quality Gate pubblico registra 33 supporti documentali, 4 fonti indipendenti e 11 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Cost-Effectiveness of Ribociclib Plus Endocrine Therapy for Premenopausal or Perimenopausal Women With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Thailand — Crossref
• Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer — Crossref
• Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors. — Europe PMC
• First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam — Crossref
• Severe Supratherapeutic international normalized ratio (INR) following concomitant Ribociclib and warfarin therapy. — Europe PMC
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer — ClinicalTrials.gov
• Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. — PubMed / NCBI
• Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations — Crossref
• Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience — Crossref
• Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors. — Europe PMC
• BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer — Crossref
• Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection — Crossref

Collegamenti nel Knowledge Graph

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer — uses intervention
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — uses intervention
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) — uses intervention
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — uses intervention
• [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer — uses intervention
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) — uses intervention
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — uses intervention
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — uses intervention
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer — uses intervention
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — uses intervention
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 100/100 · ultimo aggiornamento Settembre 29, 2026